See more : Davide Campari-Milano N.V. (DVDCF) Income Statement Analysis – Financial Results
Complete financial analysis of Calliditas Therapeutics AB (publ) (CALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calliditas Therapeutics AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BankInvest Optima 10 Akk. KL (BIV10A.CO) Income Statement Analysis – Financial Results
- Mid India Industries Limited (MIDINDIA.BO) Income Statement Analysis – Financial Results
- Onassis Holdings Corp. (ONSS) Income Statement Analysis – Financial Results
- Moongipa Capital Finance Limited (MONGIPA.BO) Income Statement Analysis – Financial Results
- MeiG Smart Technology Co., Ltd (002881.SZ) Income Statement Analysis – Financial Results
Calliditas Therapeutics AB (publ) (CALT)
About Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.21B | 802.88M | 229.35M | 874.00K | 184.83M | 0.00 | 0.00 | 497.00K | 478.00K |
| Cost of Revenue | 77.06M | 15.20M | 0.00 | 0.00 | 0.00 | 51.00K | 51.00K | 56.52M | 51.39M |
| Gross Profit | 1.13B | 787.68M | 229.35M | 874.00K | 184.83M | -51.00K | -51.00K | -56.02M | -50.91M |
| Gross Profit Ratio | 93.62% | 98.11% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | -11,271.63% | -10,650.84% |
| Research & Development | 499.54M | 414.75M | 357.49M | 241.37M | 149.83M | 99.26M | 384.00K | 40.28M | 36.89M |
| General & Administrative | 332.99M | 259.47M | 210.63M | 102.76M | 62.88M | 133.15M | 84.60M | 56.41M | 51.28M |
| Selling & Marketing | 727.74M | 515.19M | 179.60M | 38.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.01B | 774.66M | 390.23M | 141.72M | 62.88M | 133.15M | 84.60M | 56.41M | 51.28M |
| Other Expenses | 0.00 | 20.21M | 6.09M | 0.00 | 0.00 | 51.00K | 51.00K | 112.00K | 111.00K |
| Operating Expenses | 1.51B | 1.21B | 753.80M | 383.10M | 212.71M | 133.20M | 84.65M | 56.52M | 51.39M |
| Cost & Expenses | 1.59B | 1.22B | 753.80M | 383.10M | 212.71M | 133.20M | 84.65M | 56.52M | 51.39M |
| Interest Income | 29.10M | 50.20M | 102.00K | 547.00K | 926.00K | 6.00K | 0.00 | 2.00K | 0.00 |
| Interest Expense | 73.20M | 12.53M | 7.11M | 393.00K | 325.00K | 8.00K | 2.24M | 1.01M | 9.00K |
| Depreciation & Amortization | 16.59M | 12.91M | 34.43M | 2.82M | 1.82M | 51.00K | 51.00K | 112.00K | 111.00K |
| EBITDA | -367.80M | -388.82M | -483.94M | -379.40M | -25.13M | -133.14M | -84.60M | -56.40M | -51.28M |
| EBITDA Ratio | -30.48% | -52.55% | -228.67% | -43,346.80% | -13.60% | 0.00% | 0.00% | -11,348.69% | -10,727.62% |
| Operating Income | -384.40M | -421.94M | -524.46M | -379.72M | -28.02M | -132.48M | -84.51M | -56.02M | -50.91M |
| Operating Income Ratio | -31.85% | -52.55% | -228.67% | -43,446.22% | -15.16% | 0.00% | 0.00% | -11,271.63% | -10,650.84% |
| Total Other Income/Expenses | -72.62M | 5.39M | 9.47M | -53.93M | -4.48M | 1.15M | -2.29M | -395.00K | 375.00K |
| Income Before Tax | -457.02M | -409.42M | -513.37M | -436.15M | -32.50M | -132.05M | -86.79M | -56.91M | -51.01M |
| Income Before Tax Ratio | -37.87% | -50.99% | -223.84% | -49,902.86% | -17.58% | 0.00% | 0.00% | -11,451.11% | -10,672.38% |
| Income Tax Expense | 9.17M | 2.85M | -3.84M | 360.00K | 77.00K | 441.00K | 2.24M | 1.01M | 9.00K |
| Net Income | -466.19M | -412.27M | -509.54M | -436.51M | -32.58M | -132.05M | -86.79M | -56.91M | -51.01M |
| Net Income Ratio | -38.63% | -51.35% | -222.17% | -49,944.05% | -17.63% | 0.00% | 0.00% | -11,451.11% | -10,672.38% |
| EPS | -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -5.09 | -5.81 | -1.71 | -1.54 |
| EPS Diluted | -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -5.09 | -5.81 | -1.71 | -1.54 |
| Weighted Avg Shares Out | 53.67M | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 33.23M | 33.23M |
| Weighted Avg Shares Out (Dil) | 53.67M | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 33.23M | 33.23M |
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
STOCKHOLM , May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) as well as a real-world analysis of the...
CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Calliditas Therapeutics AB (NASDAQ: CALT) to Asahi Kasei Corporation for SEK 416 in cash per American Depositary Share is fair to Calliditas shareholders. Halper...
Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion
Japan's Asahi Kasei said on Tuesday it offered to acquire Calliditas Therapeutics for about 11.8 billion Swedish crowns ($1.1 billion) as part of a plan to become a global drug company.
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
STOCKHOLM , May 28, 2024 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares (" ADS ") of Calliditas Therapeutics AB (publ) (jointly the " Securityholders ") accept...
Calliditas Therapeutics AB (publ) (CALT) Q1 2024 Earnings Call Transcript
Calliditas Therapeutics AB (publ) (NASDAQ:CALT ) Q1 2024 Earnings Conference Call May 23, 2024 8:30 AM ET Company Participants Renee Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - President, North America Fredrik Johansson - CFO Conference Call Participants...
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
STOCKHOLM , May 16, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day on Thursday, May 30, 2024 at 3:00 PM CET (9:00 AM ET)....
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
STOCKHOLM , May 15, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM: CALTX) ("Calliditas"), today announced upcoming data presentations and a sponsored symposium at the 61st European Renal Association (ERA) Congress, in Stockholm, Sweden on May 23 - 26,...
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
STOCKHOLM , May 15, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the annual general meeting on Monday 17 June 2024 at 2.00 p.m.
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
STOCKHOLM , May 14, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announces that its partner Everest Medicines (HKEX: 1952.HK) ("Everest") has launched Nefecon® in China. China, which is estimated to have up to 5 million...
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
STOCKHOLM , May 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous...
Source: https://incomestatements.info
Category: Stock Reports